P53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex

Experimental Cell Research

Volumn 319, Issue 20, 2013, Pages 3104-3115

  Zhou, Zhe ^a   Cao, Ji Xiang ^a   Li, Shu Yan ^a   An, Guo Shun ^a   Ni, Ju Hua ^a   Jia, Hong Ti ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

DNA damage; E2F1; P53; PLK1; Transcription regulation

Indexed keywords

CISPLATIN; DNA; ETOPOSIDE; POLO LIKE KINASE 1; PROTEIN P53; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME DELETION 5; CONTROLLED STUDY; DNA DAMAGE; DNA PROTEIN COMPLEX; DOWN REGULATION; ENZYME ASSAY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE;

EID: 84887147168     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.09.012     Document Type: Article

References (48)

1. Barr F.A., Silljé H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nature Reviews Molecular Cell Biology 2004, 5:429-441.
2. Eckerdt F., Yuan J., Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005, 24:267-276.
3. Golsteyn R.M., Mundt K.E., Fry A.M., Nigg E.A. Cell cycle regulation of activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. Journal of Cell Biology 1995, 129:1617-1628.
4. Uchiumi T., Longo D.L., Ferris D.K. Cell cycle regulation of the human polo-like kinase (PLK) promoter. Journal of Biological Chemistry 1997, 272:9166-9174.
5. Petronczki M., Lénárt P., Peters J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Developmental Cell 2008, 14:646-659.
6. van Vugt M.A., Brás A., Medema R.H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Molecular Cell 2004, 15:799-811.
7. Toyoshima-Morimoto F., Taniguchi E., Shinya N., Iwamatsu A., Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001, 410:215-220.
8. Sumara I., Giménez-Abián J.F., Gerlich D., Hirota T., Kraft C., de la Torre C., Ellenberg J., Peters J.M. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Current Biology 2004, 14:1712-1722.
9. Brennan I.M., Peters U., Kapoor T.M., Straight A.F. Polo-like kinase controls vertebrate spindle elongation and cytokinesis. PLoS One 2007, 2:e409.
10. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. Journal of Cell Biology 1996, 135:1701-1713.
11. Liu X., Erikson R.L. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8672-8676.
12. Burkard M.E., Randall C.L., Larochelle S., Zhang C., Shokat K.M., Fisher R.P., Jallepalli P.V. Chemical genetics reveals the requirement for polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4383-4388.
13. Petronczki M., Glotzer M., Kraut N., Peters J.M. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Developmental Cell 2007, 12:713-725.
14. Takaki T., Trenz K., Costanzo V., Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Current Opinion in Cell Biology 2008, 20:650-660.
15. Yim H., Erikson R.L. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Molecular and Cellular Biology 2009, 19:2609-2621.
16. Degenhardt Y., Lampkin T. Targeting polo-like kinase in cancer therapy. Clinical Cancer Research 2010, 16:384-389.
17. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nature Reviews Drug Discovery 2010, 9:643-660.
18. Takai N., Miyazaki T., Fujisawa K., Nasu K., Hamanaka R., Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Letters 2001, 169:41-49.
19. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Research 1999, 59:2794-2797.
20. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., Altmannsberger H.M., Rübsamen-Waigmann H., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549.
21. Takahashi T., Sano B., Nagata T., Sugiyama Y., Kunieda K., Kimura M., Okano Y., Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Science 2003, 94:148-152.
22. Weichert W., Denkert C., Schmidt M., Gekeler V., Wolf G., Dietel M., Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. British Journal of Cancer 2004, 90:815-821.
23. Qin X.Q., Livingston D.M., Kaelin W.G., Adams P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10918-10922.
24. Lukas J., Petersen B.O., Holm K., Bartek J., Helin K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Molecular and Cellular Biology 1996, 16:1047-1057.
25. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10848-10853.
26. Jin S., Levine A.J. The p53 functional circuit. Journal of Cell Science 2001, 114:4139-4140.
27. Ho J., Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death & Differentiation 2003, 10:404-408.
28. O'Connor D.J., Lam E.W., Griffin S., Zhong S., Leighton L.C., Burbidge S.A., Lu X. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO Journal 1995, 14:6184-6192.
29. Nip J., Storm D.K., Eischen C.M., Cleveland J.L., Zambetti G.P., Hiebert S.W. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene 2001, 20:910-920.
30. Fogal V., Hsieh J.H., Royer C., Zhong S., Lu X. Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. EMBO Journal 2005, 24:2768-2782.
31. Taura M., Suico M.A., Fukuda R., Koga T., Shuto T., Sato T., Morino-Koga S., Okada S., Kai H. MEF/ELF4 transactivation by E2F1 is inhibited by p53. Nucleic Acids Research 2011, 39:76-88.
32. Zhu H., Chang B.D., Uchiumi T., Roninson I.B. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase II alpha genes by p21(WAF1/CIP1/SDI1). Cell Cycle 2002, 1:59-66.
33. Tategu M., Nakagawa H., Sasaki K., Yamauchi R., Sekimachi S., Suita Y., Watanabe N., Yoshid K. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor. Journal of Genetics and Genomics 2008, 35:215-224.
34. Salvatore G., Nappi T.C., Salerno P., Jiang Y., Garbi C., Ugolini C., Miccoli P., Basolo F., Castellone M.D., Cirafici A.M., Melillo R.M., Fusco A., Bittner M.L., Santoro M. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 2007, 67:10148-10158.
35. McKenzie L., King S., Marcar L., Nicol S., Dias S.S., Schumm K., Robertson P., Perkins N., Fuller-Pace F., Meek D.W. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010, 9:4200-4212.
36. Qi W., Tang Z., Yu H. Phosphorylation- and Polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1. Molecular Biology of the Cell 2006, 17:3705-3716.
37. Zhang H.J., Li W.J., Yang S.Y., Li S.Y., Ni J.H., Jia H.T. 8-Chloro-adenosine-induced E2F1 promotes p14ARF gene activation in H1299 cells through displacing Sp1 from multiple overlapping E2F1/Sp1 sites. Journal of Cellular Biochemistry 2009, 106:466-472.
38. Zhang H.J., Li W.J., Yang S.Y., Li S.Y., Ni J.H., Jia H.T. p14ARF interacts with E2F factors to form p14ARF-E2F/partner-DNA complexes repressing E2F-dependent transcription. Journal of Cellular Biochemistry 2010, 109:693-701.
39. Ji Z.X., Du C., Wu G.S., Li S.Y., An G.S., Yang Y.X, Jia R, Jia H.T., Ni J.H. Synergistic up-regulation of muscle LIM protein expression in C2C12 and NIH3T3 cells by myogenin and MEF2C. Molecular Genetics and Genomics 2009, 281:1-10.
40. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5789-5794.
41. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Molecular and Cellular Biology 2006, 26:2093-2108.
42. Bassermann F., Frescas D., Guardavaccaro D., Busino L., Peschiaroli A., Pagano M. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008, 134:256-267.
43. Ree A.H., Bratland Å., Nome R.V., Stokke T., Fodstad Ø. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 2003, 22:8952-8955.
44. Yoshihara Y., Wu D., Kubo N., Sang M., Nakagawara A., Ozaki T. Inhibitory role of E2F-1 in the regulation of tumor suppressor p53 during DNA damage response. Biochemical and Biophysical Research Communications 2012, 421:57-63.
45. Imbriano G., Gurtner A., Cocchiarella F., Di Agostino S., Basile V., Gostissa M., Dobbelstein M., Del Sal G., Piaggio G., Mantovani R. Direct p53 transcriptional repression: in vivo analysis of CCAAT-Containing G2/M promoters. Molecular and Cellular Biology 2005, 25:3737-3751.
46. Bräuninger A., Strebhardt K., Rübsamen-Waigmann H. Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter. Oncogene 1995, 11:1793-1800.
47. King S.I., Purdie C.A., Bray S.E., Quinlan P.R., Jordan L.B., Thompson A.M., Meek D.W. Immunohistochemical detection of polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Research 2012, 14:R40.
48. da Silva G.N., de Castro Marcondes J.P., de Camargo E.A., da Silva Passos Jυnior G.A., Sakamoto-Hojo E.T., Salvadori D.M.F. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Experimental Biology and Medicine 2010, 235:814-824.